The tweet was deleted by the author.
But we saved everything 🙂.
Caribou Biosciences has released updated follow-up data from its dose escalation study of CB-011 in patients with relapsed or refractory multiple myeloma.
The latest findings will be presented during an oral session at EHA2026, highlighting the ongoing evaluation of CB-011 as a potential cell therapy solution leveraging CRISPR technology. CB-011 is part of Caribou Biosciences’ pipeline targeting hard-to-treat blood cancers and aims to address unmet needs for patients whose disease has returned or not responded to prior treatments. More details are expected at the upcoming conference and are available through Caribou Biosciences’ designated channels.
Caribou Biosciences recently participated in the Jefferies Global Healthcare Conference in New York, spotlighting its work in cell therapy and CRISPR. The company also attended the BioConnect Investor Conference, where it met with biotech investors and peers. These events form part of Caribou’s ongoing efforts to engage the healthcare and investor community.